James Cook University Hospital

About: James Cook University Hospital is a healthcare organization based out in Middlesbrough, United Kingdom. It is known for research contribution in the topics: Population & Randomized controlled trial. The organization has 2183 authors who have published 2823 publications receiving 70701 citations.

SARS: Systematic Review of Treatment Effects

Abstract: Background The SARS outbreak of 2002-2003 presented clinicians with a new, life-threatening disease for which they had no experience in treating and no research on the effectiveness of treatment options The World Health Organization ( WHO) expert panel on SARS treatment requested a systematic review and comprehensive summary of treatments used for SARS-infected patients in order to guide future treatment and identify priorities for research Methods and Findings In response to the WHO request we conducted a systematic review of the published literature on ribavirin, corticosteroids, lopinavir and ritonavir (LPV/r), type I interferon (IFN), intravenous immunoglobulin ( IVIG), and SARS convalescent plasma from both in vitro studies and in SARS patients We also searched for clinical trial evidence of treatment for acute respiratory distress syndrome Sources of data were the literature databases MEDLINE, EMBASE, BIOSIS, and the Cochrane Central Register of Controlled Trials ( CENTRAL) up to February 2005 Data from publications were extracted and evidence within studies was classified using predefined criteria In total, 54 SARS treatment studies, 15 in vitro studies, and three acute respiratory distress syndrome studies met our inclusion criteria Within in vitro studies, ribavirin, lopinavir, and type I IFN showed inhibition of SARS-CoV in tissue culture In SARS-infected patient reports on ribavirin, 26 studies were classified as inconclusive, and four showed possible harm Seven studies of convalescent plasma or IVIG, three of IFN type I, and two of LPV/r were inconclusive In 29 studies of steroid use, 25 were inconclusive and four were classified as causing possible harm Conclusions Despite an extensive literature reporting on SARS treatments, it was not possible to determine whether treatments benefited patients during the SARS outbreak Some may have been harmful Clinical trials should be designed to validate a standard protocol for dosage and timing, and to accrue data in real time during future outbreaks to monitor specific adverse effects and help inform treatment

Part 11: Neonatal resuscitation: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.

Abstract: 2010;126;e1319-e1344; originally published online Oct 18, 2010; Pediatrics COLLABORATORS CHAPTER Sithembiso Velaphi and on behalf of the NEONATAL RESUSCITATION Sam Richmond, Wendy M Simon, Nalini Singhal, Edgardo Szyld, Masanori Tamura, Chameides, Jay P Goldsmith, Ruth Guinsburg, Mary Fran Hazinski, Colin Morley, Jeffrey M Perlman, Jonathan Wyllie, John Kattwinkel, Dianne L Atkins, Leon Recommendations Resuscitation and Emergency Cardiovascular Care Science With Treatment Neonatal Resuscitation: 2010 International Consensus on Cardiopulmonary http://wwwpediatricsorg/cgi/content/full/126/5/e1319 located on the World Wide Web at: The online version of this article, along with updated information and services, is rights reserved Print ISSN: 0031-4005 Online ISSN: 1098-4275 Grove Village, Illinois, 60007 Copyright © 2010 by the American Academy of Pediatrics All and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk publication, it has been published continuously since 1948 PEDIATRICS is owned, published, PEDIATRICS is the official journal of the American Academy of Pediatrics A monthly

Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome.

Abstract: Patients with neuropathic pain secondary to failed back surgery syndrome (FBSS) typically experience persistent pain, disability, and reduced quality of life. We hypothesised that spinal cord stimulation (SCS) is an effective therapy in addition to conventional medical management (CMM) in this patient population. We randomised 100 FBSS patients with predominant leg pain of neuropathic radicular origin to receive spinal cord stimulation plus conventional medical management (SCS group) or conventional medical management alone (CMM group) for at least 6 months. The primary outcome was the proportion of patients achieving 50% or more pain relief in the legs. Secondary outcomes were improvement in back and leg pain, health-related quality of life, functional capacity, use of pain medication and non-drug pain treatment, level of patient satisfaction, and incidence of complications and adverse effects. Crossover after the 6-months visit was permitted, and all patients were followed up to 1 year. In the intention-to-treat analysis at 6 months, 24 SCS patients (48%) and 4 CMM patients (9%) (p<0.001) achieved the primary outcome. Compared with the CMM group, the SCS group experienced improved leg and back pain relief, quality of life, and functional capacity, as well as greater treatment satisfaction (p